Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-52411613EnglishN2024July16Life Sciences Known Methods to Relieve Symptoms of Premenstrual Syndrome (PMS): A Review English0109Ewelina Machala-CwiklaEnglish Urszula LapinskaEnglish Piotr ZdziebloEnglish Piotr CwiklaEnglish Kamila MachalaEnglish Dominika MachalaEnglish Premenstrual syndrome (PMS) is a set of physical and psychological symptoms that occurs during the premenstrual period. It is a commonly occurring condition. The presence of PMS symptoms is associated with a deterioration in patients’ quality of life and affects their daily lives. In recent years, ongoing research has focused on identifying effective methods of alleviating PMS symptoms through both non-pharmacological and pharmacological therapies. Non-pharmacological methods used include dietary changes, physical activity and psychosocial interventions including relaxation techniques. Non-pharmacological methods appear to be a low-cost alternative to pharmacological ones. An appropriate diet rich in fruits, regular physical activity especially in the form of yoga and Pilates, and the use of relaxation and cognitive and behavioral techniques can reduce the severity of PMS symptoms. Pharmacological methods include the use of SSRI group drugs, which are the first choice for pharmacological treatment, SNRI group drugs, and drugs that affect the endocrine system, including hormonal contraception. Currently, the effect of using herbal preparations containing the extract of chaste tree (Vitex agnus-castus L.) is also being studied. It is necessary to conduct further research on the possibility of alleviating PMS symptoms both non-pharmacologically and with drugs, and to develop an optimal best practices for patients suffering from PMS symptoms. EnglishPMS, PMS management, PMS treatment, Premenstrual syndrome, Premenstrual syndrome management, Premenstrual syndrome treatmenthttp://ijcrr.com/abstract.php?article_id=4810http://ijcrr.com/article_html.php?did=4810 1. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018 Jan;218(1):68-74. 2. Bhandari S, Dwa Y, Maharjan M, Maskey S, Thakur M, Sharma S. Premenstrual Syndrome among Medical Students of a Medical College: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2023 Apr 1;61(260):347-50. 3. Morino S, Hirata H, Matsumoto D, Yokota I, Aoyama T. Patterns of premenstrual syndrome in collegiate women: A cross-sectional study. Medicine (Baltimore). 2022 Sep 2;101(35):e30186. 4. Matsumoto T, Asakura H, Hayashi T. Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder. Gynecol Endocrinol. 2013 Jan;29(1):67-73. 5. A DM, K S, A D, Sattar K. Epidemiology of Premenstrual Syndrome (PMS)-A Systematic Review and Meta-Analysis Study. J Clin Diagn Res. 2014 Feb;8(2):106-9. 6. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998 Jan 22;338(4):209-16. d 7. Yonkers KA, O‘Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 5;371(9619):1200-10. 8. Long J, Wang Y, Liu L, Zhang J. The Prominent Role of the Temporal Lobe in Premenstrual Syndrome and Premenstrual Dysphoric Disorder: Evidence From Multimodal Neuroimaging. Front Psychiatry. 2022 Jun 28;13:954211. 9. Eshetu N, Abebe H, Fikadu E, Getaye S, Jemal S, Geze Set al. Premenstrual syndrome, coping mechanisms and associated factors among Wolkite university female regular students, Ethiopia, 2021. BMC Womens Health. 2022 Mar 23;22(1):88. 10. Yi SJ, Kim M, Park I. Investigating influencing factors on premenstrual syndrome (PMS) among female college students. BMC Womens Health. 2023 Nov 10;23(1):592. 11. Alshdaifat E, Absy N, Sindiani A, AlOsta N, Hijazi H, Amarin Z, et al. Premenstrual Syndrome and Its Association with Perceived Stress: The Experience of Medical Students in Jordan. Int J Womens Health. 2022 Jun 14;14:777-85. 12. Hashim MS, Obaideen AA, Jahrami HA, Radwan H, Hamad HJ, Owais AA et al. Premenstrual Syndrome Is Associated with Dietary and Lifestyle Behaviors among University Students: A Cross-Sectional Study from Sharjah, UAE. Nutrients. 2019 Aug 17;11(8):1939. 13. Branecka-Wo?niak D, Cymbaluk-P?oska A, Kurzawa R. The impact of premenstrual syndrome on women’s quality of life - a myth or a fact? Eur Rev Med Pharmacol Sci. 2022 Jan;26(2):598-609. 14. Jaber RM, Alghzawi AO, Salameh HH. Premenstrual syndrome: consultation sources and the impact on women’s quality of life. Afr Health Sci. 2022 Mar;22(1):80-7. 15. Siminiuc R, ?urcanu D. Impact of nutritional diet therapy on premenstrual syndrome. Front Nutr. 2023 Feb 1;10:1079417. 16. Kwon YJ, Sung DI, Lee JW. Association among Premenstrual Syndrome, Dietary Patterns, and Adherence to Mediterranean Diet. Nutrients. 2022 Jun 14;14(12):2460. 17. Farpour S, Soleimani D, Moradinazar M, Samadi M. The relationship of dietary inflammatory index and dietary patterns with premenstrual syndrome among women in Kermanshah: An analytical cross-sectional study. Food Sci Nutr. 2023 May 2;11(7):4146-54. 18. Jafari F, Amani R, Tarrahi MJ. Effect of Zinc Supplementation on Physical and Psychological Symptoms, Biomarkers of Inflammation, Oxidative Stress, and Brain-Derived Neurotrophic Factor in Young Women with Premenstrual Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2020 Mar;194(1):89-95. 19. Arab A, Rafie N, Askari G, Taghiabadi M. Beneficial Role of Calcium in Premenstrual Syndrome: A Systematic Review of Current Literature. Int J Prev Med. 2020 Sep 22;11:156. 20. Pearce E, Jolly K, Jones LL, Matthewman G, Zanganeh M, Daley A. Exercise for premenstrual syndrome: a systematic review and meta-analysis of randomised controlled trials. BJGP Open. 2020 Aug 25;4(3):bjgpopen20X101032. 21. Maged AM, Abbassy AH, Sakr HRS, Elsawah H, Wagih H, Ogila AI et al. Effect of swimming exercise on premenstrual syndrome. Arch Gynecol Obstet. 2018 Apr;297(4):951-9. Erratum in: Arch Gynecol Obstet. 2024 Apr 1. 22. Mohebbi Dehnavi Z, Jafarnejad F, Sadeghi Goghary S. The effect of 8 weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome: a clinical trial study. BMC Womens Health. 2018 May 31;18(1):80. 23. El-Lithy A, El-Mazny A, Sabbour A, El-Deeb A. Effect of aerobic exercise on premenstrual symptoms, haematological and hormonal parameters in young women. J Obstet Gynaecol. 2015 May;35(4):389-92. 24. Pal A, Nath B, Paul S, Meena S. Evaluation of the effectiveness of yoga in management of premenstrual syndrome: a systematic review and meta-analysis. J Psychosom Obstet Gynaecol. 2022 Dec;43(4):517-25. 25. Çitil ET, Kaya N. Effect of pilates exercises on premenstrual syndrome symptoms: a quasi-experimental study. Complement Ther Med. 2021 Mar;57:102623. 26. Han J, Cha Y, Kim S. Effect of psychosocial interventions on the severity of premenstrual syndrome: a meta-analysis. J Psychosom Obstet Gynaecol. 2019 Sep;40(3):176-84. 27. Jose A, Nayak S, Rajesh A, Kamath N, Nalini M. Impact of relaxation therapy on premenstrual symptoms: A systematic review. J Educ Health Promot. 2022 Dec 28;11(1):401. 28. Raipure A, Patil S. The Role of Benson’s and Mitchell’s Relaxation Techniques in the Management of Premenstrual Syndrome: An In-Depth Review. Cureus. 2023 Aug 20;15(8):e43822. 29. Raipure A, Patil S. Comparative Efficacy of Mitchell’s and Benson’s Relaxation Techniques in Alleviating Pain and Improving Quality of Life Among Patients With Premenstrual Syndrome: A Randomized Controlled Trial. Cureus. 2023 Aug 21;15(8):e43877. 30. ?ener Çetin N, ?olt K?rca A. The Effect of a Mindfulness-Based Stress Reduction Program on Premenstrual Symptoms: A Randomized Controlled Trial. J Midwifery Womens Health. 2023 Sep-Oct;68(5):604-10. 31. Khodakarami B, Babakhani N, Masoumi SZ, Mohagheghi H, Farhadian M. The Effect of Cognitive-behavioral Counseling on the Resilience of Female Adolescents with Premenstrual Syndrome: A Randomized Controlled Trial. Int J Community Based Nurs Midwifery. 2023 Oct;11(4):237-46. 32. Borji-Navan S, Mohammad-Alizadeh-Charandabi S, Esmaeilpour K, Mirghafourvand M, Ahmadian-Khooinarood A. Internet- based cognitive-behavioral therapy for premenstrual syndrome: a randomized controlled trial. BMC Womens Health. 2022 Jan 8;22(1):5. 33. Schellenberg R, Zimmermann C, Drewe J, Hoexter G, Zahner C. Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine. 2012 Nov 15;19(14):1325-31. 34. Momoeda M, Sasaki H, Tagashira E, Ogishima M, Takano Y, Ochiai K. Efficacy and safety of Vitex agnus-castus extract for treatment of premenstrual syndrome in Japanese patients: a prospective, open-label study. Adv Ther. 2014 Mar;31(3):362-73. 35. He Z, Chen R, Zhou Y, Geng L, Zhang Z, Chen S, et al. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009 May 20;63(1):99-103. 36. Dimmock PW, Wyatt KM, Jones PW, O‘Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000 Sep 30;356(9236):1131-6. 37. Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013 Jun 7;2013(6):CD001396. 38. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001 Nov;98(5 Pt 1):737-44. 39. Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 2004 Oct;24(5):540-3. 40. Mazza M, Harnic D, Catalano V, Janiri L, Bria P. Duloxetine for premenstrual dysphoric disorder: a pilot study. Expert Opin Pharmacother. 2008 Mar;9(4):517-21. 41. Ramos MG, Hara C, Rocha FL. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial. Int J Neuropsychopharmacol. 2009 Sep;12(8):1081-8. 42. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone- containing oral contraceptive formulation. Contraception. 2005 Dec;72(6):414-21. 43. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet. 2011 May;113(2):103-7. 44. Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception. 2011 Jul;84(1):81-6. 45. Management of Premenstrual Syndrome: Green-top Guideline No. 48. BJOG. 2017 Feb;124(3):e73-e105. 46. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004 Jun;111(6):585-93. 47. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod. 2004 Sep;19(9):2152-5.

Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-52411613EnglishN2024July16Life Sciences Positive Effects of Botulinum Toxin On Patients Suffering From Depression     English1013Urszula LapinskaEnglish Rafal LapinskiEnglish Ewelina Machala-CwiklaEnglish Dominika MachalaEnglish Piotr CwiklaEnglish Kamila MachalaEnglish Piotr ZdziebloEnglish Due to number of patients with depression constantly growing, new methods of treating and improving their well-being are being looked for. Depression has remained among the top diseases in terms of prevalence worldwide for years, and part of the patient group is resistant to drug treatment. Research in the area of improving the well-being of patients struggling with depression and facilitating their treatment process, such as through lifestyle changes, continues to expand. In 2006, the first publication suggesting a positive effect of botulinum toxin type A in patients suffering from depression appeared, and consistently in the following years more and more scientific papers appeared. Botulinum toxin treatments for the face are very popular; it is a drug registered for many medical indications. So what information do we have on this subject at this point? Could depression potentially become one of the indications for botulinum toxin use in the future? EnglishBotulinum toxin, Botulinum toxin in depression, Depression, Facial wrinkles depression, Depression syndromes, Depression lifestyle, Depression therapy, Botulinum toxin usagehttp://ijcrr.com/abstract.php?article_id=4811http://ijcrr.com/article_html.php?did=4811 1. World Health Organization (WHO). Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/ depression Access date: 25.05.2024 2. Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis. Br J Clin Psychol. 2022 Jun;61(2):287-305. doi: 10.1111/bjc.12333. Epub 2021 Sep 26. PMID: 34569066. 3. Lin J, Zou L, Lin W, Becker B, Yeung A, Cuijpers P, Li H. Does gender role explain a high risk of depression? A meta-analytic review of 40 years of evidence. J Affect Disord. 2021 Nov 1;294:261-278. doi: 10.1016/j.jad.2021.07.018. Epub 2021 Jul 16. PMID: 34304081. 4. Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. Psychol Bull. 2017 Aug;143(8):783-822. doi: 10.1037/bul0000102. Epub 2017 Apr 27. PMID: 28447828; PMCID: PMC5532074. 5. Hardeveld F, Spijker J, De Graaf R, Hendriks SM, Licht CM, Nolen WA, Penninx BW, Beekman AT. Recurrence of major depressive disorder across different treatment settings: results from the NESDA study. J Affect Disord. 2013 May;147(1-3):225- 31. doi: 10.1016/ j.jad.2012.11.008. Epub 2012 Dec 4. PMID: 23218899. 6. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999 Jul;156(7):1000-6. doi: 10.1176/ ajp.156.7.1000. PMID: 10401442. 7. International Society of Aesthetic Plastic Surgery. 2023 ISAPS International survey on aesthetic/cosmetic procedures performed in 2022. https://www.isaps.org/media/a0qfm4h3/isapsglobal- survey_2022.pdf Access date: 25.05.2024 8. Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014 Aug 1;90(3):168-75. PMID: 25077722. https:// www.aafp.org/pubs/afp/issues/2014/0801/ p168.html Access date: 25.05.2024 9. Gostimir M, Liou V, Yoon MK. Safety of Botulinum Toxin A Injections for Facial Rejuvenation: A Meta-Analysis of 9,669 Patients. Ophthalmic Plast Reconstr Surg. 2023 Jan-Feb 01;39(1):13-25. doi: 10.1097/IOP.0000000000002169. Epub 2022 Mar 30. PMID: 35353777. 10. Yiannakopoulou E. Botulinum toxin and anal fissure: efficacy and safety systematic review. Int J Colorectal Dis. 2012 Jan;27(1):1-9. doi: 10.1007/s00384-011-1286-5. Epub 2011 Aug 6. PMID: 21822595. 11. Shaterian N, Shaterian N, Ghanaatpisheh A, Abbasi F, Daniali S, Jahromi MJ, Sanie MS, Abdoli A. Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain Res Manag. 2022 Mar 31;2022:3284446. doi: 10.1155/2022/3284446. PMID: 35401888; PMCID: PMC8989603. 12. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004315. doi: 10.1002/14651858.CD004315.pub2. Update in: Cochrane Database Syst Rev. 2016 May 13;(5):CD004315. doi: 10.1002/14651858.CD004315.pub3. PMID: 15674941. 13. Bapir R, Bhatti KH, Eliwa A, García-Perdomo HA, Gherabi N, Hennessey D, Magri V, Mourmouris P, Ouattara A, Perletti G, Philipraj J, Stamatiou K, Trinchieri A, Buchholz N. Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials. Arch Ital Urol Androl. 2022 Dec 28;94(4):492-506. doi: 10.4081/ aiua.2022.4.492. PMID: 36576454. 14. Cohen JL, Fagien S, Ogilvie P, De Boulle K, Carruthers J, Cox SE, Kelly R, Garcia JK, Sangha S. High Patient Satisfaction for up to 6 Months With OnabotulinumtoxinA Treatment for Upper Facial Lines. Dermatol Surg. 2022 Nov 1;48(11):1191- 1197. doi: 10.1097/DSS.0000000000003585. Epub 2022 Oct 5. PMID: 36342250; PMCID: PMC9632938. 15. Wang X, Arafa A, Liu K, Eshak ES, Hu Y, Dong JY. Combined healthy lifestyle and depressive symptoms: a meta-analysis of observational studies. J Affect Disord. 2021 Jun 15;289:144- 150. doi: 10.1016/j.jad.2021.04.030. Epub 2021 Apr 26. PMID: 33979724. 16. Kunugi H. Depression and lifestyle: Focusing on nutrition, exercise, and their possible relevance to molecular mechanisms. Psychiatry Clin Neurosci. 2023 Aug;77(8):420-433. doi: 10.1111/ pcn.13551. Epub 2023 Apr 25. PMID: 36992617. 17. Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006 May;32(5):645-9; discussion 649-50. doi: 10.1111/ j.1524-4725.2006.32136.x. PMID: 16706759. 18. Parsaik AK, Mascarenhas SS, Hashmi A, Prokop LJ, John V, Okusaga O, Singh B. Role of Botulinum Toxin in Depression. J Psychiatr Pract. 2016 Mar;22(2):99-110. doi: 10.1097/ PRA.0000000000000136. PMID: 27138078. 19. Crowley, Jiwon S. M.D.; Silverstein, Max L. B.S.; Reghunathan, Meera M.D.; Gosman, Amanda A. M.D.. Glabellar Botulinum Toxin Injection Improves Depression Scores: A Systematic Review and Meta-Analysis. Plastic and Reconstructive Surgery 150(1):p 211e-220e, July 2022. doi: 10.1097/ PRS.0000000000009240 20. Heckmann M, Teichmann B, Schroder U, Sprengelmeyer R, Ceballos- Baumann AO. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol. (2003) 49:213–6. doi: 10.1067/S0190-9622(03)00909-5 21. Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol. (2009) 8:24–6. doi: 10.1111/j.1473-2165.2009.00419.x 22. Schwartz GE, Fair PL, Salt P, Mandel MR, Klerman GL. Facial muscle patterning to affective imagery in depressed and nondepressed subjects. Science. (1976) 192:489–91. doi: 10.1126/ science.1257786 23. BURGEN AS, DICKENS F, ZATMAN LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949 Aug;109(1-2):10-24. doi: 10.1113/ jphysiol.1949.sp004364. PMID: 15394302; PMCID: PMC1392572. 24. Qian H, Shao F, Lenahan C, Shao A and Li Y (2020) Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Psychiatry 11:603087. doi: 10.3389/fpsyt. 2020.603087 25. Ni L, Chen H, Xu X, Sun D, Cai H, Wang L, Tang Q, Hao Y, Cao S, Hu X. Neurocircuitry underlying the antidepressant effect of retrograde facial botulinum toxin in mice. Cell Biosci. 2023 Feb 13;13(1):30. doi: 10.1186/s13578-023-00964-1. PMID: 36782335; PMCID: PMC9926702.